- Home
- VOR vs DNA Comparison
VOR vs DNA Comparison
Compare VOR & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VOR | DNA |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.6M | 607.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | VOR | DNA |
|---|---|---|
| Price | $15.85 | $9.62 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 2 |
| Target Price | ★ $64.78 | $10.50 |
| AVG Volume (30 Days) | 709.0K | ★ 981.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $5.00 |
| 52 Week High | $49.95 | $17.58 |
Technical Indicators
Market Signals| Indicator | VOR | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 62.12 | 54.31 |
| Support Level | $11.27 | $9.05 |
| Resistance Level | $16.80 | $10.05 |
| Average True Range (ATR) | 1.23 | 0.71 |
| MACD | 0.33 | 0.03 |
| Stochastic Oscillator | 74.72 | 59.83 |
Price Performance
Historical ComparisonAbout VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.